• About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Contact
  • Login

o2h-ventures

  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • Documents
  • news
    • Press releases
    • Blog
    • Press Coverage
    • Events
  • Contact
  • Login

the o2h human health funds

Innovation in UK lifesciences & technology

Open

o2h knowledge-intensive EIS fund

The o2h human health knowledge-intensive EIS fund is the first HMRC approved KI fund in the UK that will invest in EIS seed stage KI companies covering novel drug discovery and AI technologies.

Open

the o2h SEIS fund

The human health SEIS fund will invest in SEIS qualifying seed stage companies covering novel drug discovery along with enabling services, tools and AI Technologies.

Closed

the o2h S/EIS fund

The o2h human health S/EIS fund is a hybrid fund that is investing in EIS and SEIS qualifying seed stage companies covering novel drug discovery along with enabling services, tools and AI technologies.

Speak to a member of our team Contact us
o2h-ventures
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years.
Useful Links
  • About Us
  • Blog
  • Documents Centre
  • Contact Us
  • Team
News
  • May 2022, o2h Ventures Fund Newsletter, SEIS fund close deadline June 30th 2022
  • The “o2h human health KI EIS fund” makes an investment into Neurocentrx
  • o2h Ventures Deal Pipeline, KI EIS Fund closing on 5th April 2022
Connect with us
  • linkedin
  • twitter
  • instagram
  • facebook
© 2022 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us
o2h ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors